GlobeNewsWire
08 Jun 2026, 05:00 UTC · 9h ago
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
GlobeNewsWire
08 Jun 2026, 05:00 UTC · 9h ago
Story key points
4 claims · impact-rated
Nurix Therapeutics entered a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, a BTK degrader. — A partnership with a global giant like Roche provides massive validation of the asset and significant infrastructure for commercial success.
+0.80Nurix will receive an immediate upfront cash payment of $700 million and potential milestones totaling up to $2.3 billion. — A substantial non-dilutive cash infusion significantly improves the company's balance sheet and runway.
+0.70The clinical development plan expands bexobrutideg beyond hematology into neurology and immunology, including Phase 2 trials for multiple sclerosis and chronic spontaneous urticaria. — Expanding the total addressable market into non-oncology indications increases the long-term valuation potential of the drug.
+0.50Continue reading
6 related stories
Top 1 mover · tap to explore
Nurix and Roche will equally split profits and losses for U.S. commercialization, while Nurix will receive royalties on ex-U.S. sales. — The co-commercialization structure allows Nurix to retain significant upside from the drug's success rather than taking a simple exit.
+0.40Ticker attribution
Model heads
The company secured a high-value collaboration with an upfront payment of $700 million and potential milestones up to $2.3 billion.
The company is expanding its B-cell targeted therapy portfolio with a potential best-in-class BTK degrader.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
12 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
